+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Apoptosis Regulator BAX - Drugs In Development, 2021

  • PDF Icon

    Drug Pipelines

  • 46 Pages
  • June 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5359585
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions.

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 8 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Ophthalmology which include indications Lung Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, Hepatocellular Carcinoma, Melanoma, Myocardial Infarction and Parkinson's Disease.

The latest report Apoptosis Regulator BAX - Drugs In Development, 2021, outlays comprehensive information on the Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX)
  • The report reviews Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Introduction
  • Report Coverage

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Overview
Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Companies Involved in Therapeutics Development
  • Genervon Biopharmaceuticals LLC
  • Lytix Biopharma AS
  • PHD Biosciences

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Drug Profiles
CYD-211 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

GM-6 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

LTX-401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecule to Activate Apoptosis Regulator BAX for Lung Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecule to Activate BAX for Acute Myelocytic Leukemia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecule to Inhibit BAX for Myocardial Infarction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecules to Inhibit BAX for Ophthalmology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

SMBA-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Dormant ProductsApoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Product Development Milestones
Featured News & Press Releases
  • Feb 26, 2018: Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference
  • Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS
  • Apr 06, 2017: Lytix Biopharma presents poster on LTX-401 at AACR in Washington April 2017
  • Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published
  • Jan 10, 2017: Genervon Releases ALS, PD and AD Disease­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm
  • Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways
  • Sep 21, 2016: Lytix Biopharma develops second generation oncolytic molecules for deep seated tumors
  • Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS
  • May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604
  • May 03, 2016: GM604 to Be Granted “Orphan Drug” Status in Europe
  • Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression
  • Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease
  • Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA
  • Jan 08, 2015: Genervon Announces ALS Compassionate Use Results
  • Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Genervon Biopharmaceuticals LLC, 2021
  • Pipeline by Lytix Biopharma AS, 2021
  • Pipeline by PHD Biosciences, 2021
  • Dormant Projects, 2021

List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Genervon Biopharmaceuticals LLC
  • Lytix Biopharma AS
  • PHD Biosciences